1. Ainsworth NJ, Brender R, Gotlieb N, Mulsant BH, Blumberger DM, Karp JF et al. Association between lean muscle mass and treatment-resistant late-life depression in the IRL-GRey randomized controlled trial. Int Psychogeriatr 2023; 35: 707-716.
2.
Ali E, Latif F, Mashkoor Y, Gul Z, Malik F, Hanif M et al. Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Asian J Psychiatry 2024; 95: 104005.
3.
Altmann HM, Kazan J, Gebara MA, Roose SP, Karp JF, Lenze EJ et al. Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial. Am J Geriatr Psychiatry 2022; 30: 994-1002.
4.
Bai B, Li Y, Chen X, Wang Y, Zhang K, Zhang X et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry 2025; 25: 338.
5.
Beunk L, Nijenhuis M, Soree B, van der Sijs H, Guchelaar HJ, van Schaik RHN et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 2024; 32: 278-285.
6.
Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
7.
Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016; 77: 371-378.
8.
Earley WR, Guo H, Németh G, Hincapie-Castillo JM, Herman BK, McIntyre RS. Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 2018; 48: 62-80.
9.
Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2018; 33: 312-321.
10.
Fava M, Masand PS, Maletic V, Christensen M, Szatmári B, Barabássy A et al. Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. J Clin Psychiatry 2025; 86: 24m15506.
11.
Gebara MA, DiNapoli EA, Kasckow J, Karp JF, Lenze EJ, Mulsant BH et al. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychiatry 2018; 33: e330-e335.
12.
Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Papakostas GI, Fava M et al. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord 2025; 390: 119836.
13.
Hsu JH, Mulsant BH, Lenze EJ, Karp JF, Reynolds CF, Blumberger DM et al. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. Am J Geriatr Psychiatry 2016; 24: 918-922.
14.
Ji M, Feng J, Liu G. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2024; 19: e0299020.
15.
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med 2023; 53: 4064-4082.
16.
Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF, Blumberger DM et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med 2023; 388: 1067-1079.
17.
McIntyre RS, Maletic V, Masand P, Christensen M, Szatmári B, Barabássy A et al. The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord 2025; 385: 119366.
18.
Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Peusic V, Molden E et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021; 78: 270-280.
19.
Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord 2022; 302: 385-400.
20.
Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Mathew SJ, Fava M et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry 2024; 29: 2287-2295.
21.
Pozuelo Moyano B, Gomez Bautista D, Porras Ibarra KJ, Sanchez-Mico M, Lopez-Diaz A, Giner L et al. Systematic review of clinical effectiveness of interventions for treatment resistant late-life depression. Ageing Res Rev 2025; 107: 102710.
22.
Riesenberg R, Yeung PP, Rekeda L, Earley W, Németh G, Fava M. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry 2023; 84: 22m14643.
23.
Sachs GS, Yeung PP, Rekeda L, Earley W, Németh G, Fava M. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry 2023; 180: 241-251.
24.
Scott F, Hampsey E, Gnanapragasam S, Strawbridge R, Young AH. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol 2023; 37: 268-278.
25.
Seshadri A, Wermers ME, Habermann TJ, Singh B. Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis. Prim Care Companion CNS Disord 2021; 23: 20r02799.
26.
Takeshima M, Umakoshi A, Omori Y, Kikuchi Y, Tsuda H, Akechi T. et al. Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial. Psychopharmacology 2024; 241: 1555-1563.
27.
Wang J, Li W, Li M, Wu Y, Zhu Y. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis. Medicine (Baltimore) 2023; 102: e34670.
28.
Yan Y, Yang X, Wang M, Zhao L, Zhang Y, Zhang Q et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol Med 2022; 52: 2224-2231.
